COVID-19
At AdventHealth our goal is to continue fighting COVID-19 until it is a thing of the past. Ongoing clinical trials and research studies help by contributing knowledge to the fight against COVID-19.
Steven R. Smith, MD
Chief Scientific Officer, Senior Vice President of AdventHealth
, , , , , , , , , , , , , , , Translational Research, Infectious Disease, ,
Overview
Dr. Steven R. Smith is the Senior Vice President and Chief Scientific Officer of AdventHealth guiding the research vision for AdventHealth across the system. AdventHealth is a multi-state hospital system with 50 hospital campuses, more than 1,200 care sites and over 80,000 team members. Dr. Smith's oversight includes all research operations, services and oversight for the nine states in which we serve.
Dr. Smith earned his medical degree from the University of Texas Health Science Center in San Antonio, Texas in 1988. Smith completed his residency in internal medicine at Baylor University Medical Center in Dallas, Texas and subsequently completed a two-year fellowship in clinical endocrinology and metabolism at the Ochsner Clinic and Hospital in New Orleans, Louisiana. He was a faculty member at Pennington Biomedical Research Center for 15 years prior to joining AdventHeaIth.
Smith's scientific work bridges the gap between cell/molecular biology and clinical care. Translational science involves translating discoveries in the basic sciences to the clinic and importantly informing basic science with clinical phenotyping, biospecimens and modern molecular methods.
Smith's research is focused on obesity, diabetes and the metabolic origins of cardiovascular disease. He is specifically focused on how individuals differ in their ability to adapt to diets high in fat and understanding how obesity leads to type- 2 diabetes. Using the translational medicine approach, Dr. Smith discovered that many obese people have an inability to burn fat and a new hormonal control system to increase fat and energy metabolism. Most importantly, the discovery that the inability to burn fat is programmed into muscle cells provides a novel way to identify and test new treatments for obesity and diabetes. More recently, Dr. Smith's research program focuses on epigenetic programming of adipose tissue growth and function as well as the role of the human gut microbiome on the development of obesity. His translational work demonstrated that each person is unique at the molecular level suggesting new ways to match therapies to the individual; this is the goal of field 'personalized medicine.'
Dr. Smith's research is currently funded by the NIH with two RO1 Grants, industry and philanthropic support. In his research career, Dr. Smith has published more than 200 peer-reviewed scientific manuscripts, reviews and chapters.
Articles
Transcriptional and DNA Methylation Signatures of Subcutaneous Adipose Tissue and Adipose-Derived Stem Cells in PCOS Women
CELLS
2022
Caloric restriction in humans reveals immunometabolic regulators of health span
SCIENCE
2022
Physiology of Energy Expenditure in the Weight-Reduced State
Obesity
2021
Energy intake as a short-term biomarker for weight loss in adults with obesity receiving liraglutide: A randomized trial
OBESITY SCIENCE & PRACTICE
2021
A Novel Endocrine Role for the BAT-Released Lipokine 12,13-diHOME to Mediate Cardiac Function
CIRCULATION
2021
A Metabolomic Signature of Glucagon Action in Healthy Individuals With Overweight/Obesity
JOURNAL OF THE ENDOCRINE SOCIETY
2021
Twenty-four hour assessments of substrate oxidation reveal differences in metabolic flexibility in type 2 diabetes that are improved with aerobic training
DIABETOLOGIA
2021
Reliability of measurements of energy expenditure and substrate oxidation using whole-room indirect calorimetry
Obesity
2021
DNA Methylation as a Marker of Body Shape in Premenopausal Women
FRONTIERS IN GENETICS
2021
Developing a model for estimating the activity of colonic microbes after intestinal surgeries
PLOS ONE
2021
Education & Training
Education
University of Texas Health Science Center, San Antonio, TX
Residency
Baylor University Medical Center, Dallas, TX
Fellowship
Ochsner Clinic and Hospital, New Orleans, LA
Specialty
Obesity & Diabetes
Associated Clinical Trials
NCT02939703
MICROBIOME: Integrating Quantitative Energetics Determines the Microbiome's Contribution to Energy Balance
The purpose of this study is to collect data to examine how diet impacts the composition and function of the bacteria in your large intestine. This community of bacteria is called the gut microbiome. Recent evidence suggests th ...
NCT03653091
C-40000: Randomized, Double-Blind, Sham-Controlled, Prospective, Multi-Center Pilot Study To Evaluate The Safety And Effectiveness Of Duodenal Mucosal Resurfacing Using The Revita System In The Treatment Of Type 2 Diabetes
This study is being run for research purposes. The study device, the Fractyl Revita System, is being tested for the treatment of Type 2 diabetes. The purpose of this study is to learn more about the use of the Revita System for ...
NCT02849977
RHYTHM/GO-ID: Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers
The purpose of this study is to identify people who have a rare genetic cause of obesity. You are being asked to participate in this research study because you indicated that either you or your child was severely overweight at ...
NCT04034706
EPIC: Transcriptomic and epigenetic characterization of the subcutaneous fat depots in PCOS women
This study is currently enrolling.
Polycystic ovary syndrome, or PCOS, is a hormonal condition where your reproductive hormones are out of balance. PCOS is also associated with an increased risk to become obese and a male-like fat tissue distribution in women (a ...
NCT02226640
ORIGINS: Uncovering the ORIGIN’ of diabetes
The purpose of this study is to collect data to help researchers better understand the various causes of Type 2 Diabetes Mellitus (T2DM). This information may lead to T2DM treatment options that are more tailored to an individ ...
PLACENTA DM: Maternal Adipose Tissue and Placental Dysfunction Programs the Fetus for Type 2 Diabetes
The purpose of this study is to discover the characteristics of pregnant women which increases risk for their babies to develop diabetes, later on in life. Information obtained in this study may assist researchers to develop ea ...
NCT01925989
BIDO: Evaluation of the Effects of LY2605541 on Respiratory Quotient During Sleep and Response to Hyperinsulinemia Compared with that of Insulin Glargine in Patients with Type 1 Diabetes Mellitus
This study is being done to find out more about LY2605541, which is an investigational drug being developed for the treatment of diabetes mellitus. This drug has not yet been approved by the Food and Drug Administration (FDA). ...
NCT01923389
B2901009/PFIZER FIRST: A Phase 1, Placebo-Controlled, Randomized Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Intravenous Doses of PF-05231023 in Obese Adult Subjects
PF-05231023 is an investigational new drug. “Investigational” means the study drug is being tested and has not yet been approved by the United States Food and Drug Administration . The study drug is being developed for the tr ...
NCT03376802
ADORE: A randomized, double-blind, placebo-controlled study to assess the effect of repeated subcutaneous doses of SAR425899 on energy expenditure and safety in overweight to obese male and female subjects
The primary purpose of the study is to test if SAR425899 can affect energy expenditure.
ISIS: A Double Blind, Randomized, Placebo-controlled, Single Center, Phase 2a Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 463588 Administered Subcutaneously Once Weekly for 13 Weeks in Obese Patients
The purpose of this research study is to find out more about the safety and tolerability of an investigational drug called ISIS 463588. This experimental drug is not approved by any regulatory health agency. ISIS 463588 is giv ...
NCT03041792
A9001498: A 6-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TWO‑ARM, PARALLEL METHODOLOGY STUDY TO ASSESS THE EFFECT OF LIRAGLUTIDE ON FOOD INTAKE IN OBESE SUBJECTS
The purpose of this research study is to assess the effect of liraglutide administration on food intake in obese patients. Liraglutide is a medication that is FDA approved for the treatment of obesity, known as Saxenda Liraglut ...
GLEE: Effects of Glucagon Administration on Energy Expenditure
The purpose of this study is to collect data to help researchers better understand the effects of glucagon on the amount of calories you burn. This will provide important information on the development of new forms of treatment ...
ISTAR: Intestinal sweet taste receptor function and adaptation to dietary sugars and sweeteners
The purpose of this study is to collect data that will help researchers better understand the various causes of obesity and diabetes; particularly to understand how consumption of NCASs affects the way your body uses nutrients. ...